The Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of drug products and drug candidates. To date, these collaborative arrangements have included out-licenses of and options to out-license internally developed products and drug candidates to other parties, in-licenses of products and drug candidates from other parties, and profit- and cost-sharing arrangements. These arrangements may include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing and reimbursement arrangements, royalty payments, and profit sharing. For detailed descriptions of each arrangement, see the Company’s Annual Report.

For the three and six months ended June 30, 2026 and 2025, the Company’s other revenue consisted primarily of royalty revenue from IMDELLTRA® sales outside of China under the Amgen collaboration agreement and revenue generated under the Novartis broad markets agreement.


	Three Months Ended		Six Months Ended
	June 30,		June 30,
		2026	2025	2026	2025
Other Revenue		$	$	$	$
Amgen royalty revenue		18,823	9,033	37,120	14,552
Novartis broad markets revenue		4,956	3,320	10,219	6,842
Other		1,498	871	4,047	579
Other Revenue		25,277	13,224	51,386	21,973

During the three and six months ended June 30, 2026 and 2025, the Company recorded the following amounts related to its collaboration arrangement with Amgen. For a detailed description of the arrangement and related rights and obligations, see the Company’s Annual Report. The Company is still in the commercialization period for XGEVA®, KYPROLIS® and BLINCYTO® in China.

Amounts recorded related to the Company’s portion of the co-development funding on the pipeline assets for the three and six months ended June 30, 2026 and 2025 were as follows:


	Three Months Ended		Six Months Ended
	June 30,		June 30,
		2026	2025	2026		2025
		$	$	$		$
BeOne’s portion of the development funding		59,818	52,196	117,866		92,715
Less: Amortization of research and development cost share liability		29,518	25,757	58,163		45,569
Research and development expense		30,300	26,439	59,703		47,146

						As of
						June 30, 2026
						$
Remaining portion of development funding cap					12,527


	As of
	June 30,	December 31,
	2026	2025
	$	$
Research and development cost share liability, current portion	6,182	64,345

Total research and development cost share liability	6,182	64,345

The total reimbursement paid under the commercial profit-sharing agreement for product sales is classified in the income statement for the three and six months ended June 30, 2026 and 2025 as follows:


	Three Months Ended		Six Months Ended
	June 30,		June 30,
		2026	2025	2026	2025
		$	$	$	$
Cost of sales - product		12,660	9,533	23,913	17,027
Research and development		(1,132)	(1,597)	(1,325)	(2,109)
Selling, general and administrative		(27,083)	(25,037)	(53,525)	(48,985)
Total		(15,555)	(17,101)	(30,937)	(34,067)

The Company purchases commercial inventory from Amgen to distribute in China. Inventory purchases amounted to $132,019 and $255,710 for the three and six months ended June 30, 2026, respectively, and $73,288 and $136,032 for the three and six months ended June 30, 2025, respectively. Net amounts payable to Amgen was $110,503 and $79,097 as of June 30, 2026 and December 31, 2025, respectively.

The Company has in-licensed the rights to develop, manufacture and, if approved, commercialize multiple development stage drug candidates globally or in specific territories. These arrangements typically include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing arrangements, royalty payments, and profit sharing.

Upfront and milestone payments incurred under these arrangements for the three and six months ended June 30, 2026 and 2025 are set forth below. All upfront and development milestones were expensed to research and development expense. All regulatory and commercial milestones were capitalized as intangible assets and are being amortized over the remainder of the respective product patent or term of the commercialization agreements.


		Three Months Ended		Six Months Ended
		June 30,		June 30,
			2026	2025	2026	2025
Payments due to collaboration partners	Classification		$	$	$	$
Upfront payments	Research and development expense		19,974	500	20,518	500
Development milestones incurred	Research and development expense		3,313	—	3,313	—
Regulatory and commercial milestone payments	Intangible asset		—	20,000	—	20,000
Total			23,287	20,500	23,831	20,500